Summary
The evaluated claims appear to be about ketorolac tromethamine ophthalmic solution (eye drops) and related side effects/patent pricing, but the provided FDA label excerpts are for ketorolac tromethamine oral tablets. Most claims are therefore unsupported or effectively contradicted by the mismatch in product and labeled indication (oral tablets for short-term adult acute pain), creating a high risk of misleading and unsafe information.
Category Scores
Accurate Statements
Ketorolac is an older drug.
No relevant information in the provided label excerpts (Indications, Dosage, Contraindications, Warnings, Adverse Reactions, Interactions, Specific Populations, Description, Clinical Pharmacology) addresses drug age/market history.
The primary patents for ketorolac have long expired.
No relevant information in the provided label excerpts addresses patent status.
Because ketorolac patents have long expired, generic versions are widely available.
No relevant information in the provided label excerpts addresses generic availability.
Unsupported Statements
Ketorolac tromethamine ophthalmic solution is a nonsteroidal anti-inflammatory drug (NSAID).
The provided label excerpts are for ketorolac tromethamine oral tablets; ophthalmic solution claims are not supported by the provided labeling.
Ketorolac tromethamine ophthalmic solution is used to treat pain and inflammation in the eye.
The provided labeling indicates ketorolac tromethamine tablets are for short-term (≤5 days) management of moderately severe acute pain in adults requiring opioid-level analgesia; no ophthalmic indication is provided in the excerpts.
Ketorolac tromethamine ophthalmic solution is often prescribed following eye surgery.
No ophthalmic post-surgical use is stated in the provided labeling; the label excerpt instead describes tablet use as postoperative continuation after IV/IM in a postoperative setting for acute pain.
Ketorolac tromethamine ophthalmic solution is prescribed for certain types of ocular inflammation.
No ocular inflammation indication is provided in the provided labeling excerpts.
Common side effects of ketorolac eye drops include temporary stinging or burning upon application.
The provided label excerpts list common adverse experiences for ketorolac tromethamine in general (e.g., GI experiences, abnormal renal function, anemia, dizziness, edema, headaches, increased bleeding time, hypertension) but do not provide eye-drop-specific local ocular irritation adverse reactions.
Common side effects of ketorolac eye drops include blurred vision.
Blurred vision is not listed in the provided adverse reaction excerpt for ketorolac tablets.
Common side effects of ketorolac eye drops include eye redness.
Eye redness is not listed in the provided adverse reaction excerpt for ketorolac tablets.
Common side effects of ketorolac eye drops include sensitivity to light.
Photophobia/light sensitivity is not listed in the provided adverse reaction excerpt for ketorolac tablets.
More serious, less common side effects of ketorolac eye drops can include delayed healing.
Delayed healing is not mentioned in the provided adverse reaction excerpt.
More serious, less common side effects of ketorolac eye drops can include corneal problems.
Corneal problems are not mentioned in the provided adverse reaction excerpt.
More serious, less common side effects of ketorolac eye drops can include allergic reactions.
While anaphylactic/anaphylactoid reactions are discussed in the label, the specific wording is eye-drop context and “allergic reactions” as a general category is not explicitly supported as a less common eye-drop adverse effect in the provided excerpt.
Generic ketorolac tromethamine ophthalmic solution 0.5% can range from approximately $10 to $30 for a 5 mL bottle.
The provided label excerpts do not include pricing or availability information.
Contradictions
High
AI Statement
Ketorolac tromethamine ophthalmic solution is used to treat pain and inflammation in the eye.
Label Reference
Provided label excerpt for ketorolac tromethamine tablets: Indicated for short-term (≤5 days) management of moderately severe acute pain in adult patients requiring analgesia at the opioid level, usually postoperative; no ophthalmic pain/inflammation indication provided.
Moderate
AI Statement
Ketorolac tromethamine ophthalmic solution is often prescribed following eye surgery.
Label Reference
Provided label excerpts describe tablets as continuation treatment following IV/IM dosing in a postoperative setting for acute pain; no eye-surgery ophthalmic use is stated.
Important Omissions
Key labeled administration/dosing constraints for ketorolac tromethamine tablets: total combined duration of IV/IM and tablets not to exceed 5 days in adults; oral formulation only as continuation after IV/IM dosing and should not be given as initial dose.
Importance:
High
The provided label includes multiple boxed/warning-level serious risks (GI ulceration/bleeding/perforation; cardiovascular thrombotic events; renal effects; bleeding risk; anaphylactoid reactions) that were not addressed despite the response making multiple safety-related adverse reaction claims (eye-drop context).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims are about an ophthalmic solution and its ocular adverse effects and indications, but the provided FDA excerpts are for oral tablets with a different indication and serious boxed-warning risks. Product mismatch plus unsupported safety/indication statements could mislead treatment expectations and risk mitigation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Product/route mismatch: claims are for ketorolac ophthalmic solution and ocular adverse effects, but the supplied FDA label excerpts are for ketorolac tromethamine oral tablets and do not support ophthalmic indications or eye-drop-specific adverse reactions.
Suggested Improvement
Restrict claims to the provided label’s scope (oral tablets) and supported labeled indications (short-term adult acute pain requiring opioid-level analgesia, usually postoperative). Do not state ophthalmic indications/side effects or pricing unless supported by the corresponding FDA label for the ophthalmic formulation and by an authorized data source.